세계의 트라넥삼산 시장(-2035년) : 제제 유형, 용도, 유통경로, 최종사용자, 제형, 지역별

Global Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

Market Overview

The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024.

The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation.

The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth as a result of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients.

Market Segmentation Analysis

In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention.

In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for haemorrhage management is the reason for this growth.

Analysis of the Region

In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions.

Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments.

Major Players

Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
• 1.2 MARKET ATTRACTIVENESS ANALYSIS
• 1.3 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE
• 1.4 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION
• 1.5 GLOBAL TRANEXAMIC ACID MARKET, BY END USER
• 1.6 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research Data Flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research Data Flow:
  • 3.5.2 Primary Research: Number of Interviews conducted
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Type
• 3.8 DATA MODELING
  • 3.8.1 Microeconomic Factor Analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 GROWTH PARAMETERS MAPPED - DRIVERS
  • 4.2.1 Increasing Surgical Procedures
  • 4.2.2 Growing Prevalence of Trauma Cases
  • 4.2.3 Growing Prevalence of Heavy Menstrual Bleeding (HMB)
• 4.3 WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
  • 4.3.1 Stringent Regulatory Requirements
  • 4.3.2 High R&D Costs for New Formulations
• 4.4 MARKET OPPORTUNITIES MAPPED
  • 4.4.1 Rising Demand for Minimally Invasive & Non-Surgical Treatment Options
  • 4.4.2 Untapped Potential in Emerging Markets

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 Bargaining Power of Suppliers
  • 5.1.2 Bargaining Power of Buyers
  • 5.1.3 Threat of New Entrants
  • 5.1.4 Threat of Substitutes
  • 5.1.5 Intensity of Rivalry
• 5.2 COVID-19 IMPACT ANALYSIS
  • 5.2.1 Impact on R & D
  • 5.2.2 Impact on Supply Chain
  • 5.2.3 Impact on Pricing

6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE

• 6.1 INTRODUCTION
• 6.2 ORAL
• 6.3 INJECTABLE
• 6.4 TROPICAL

7 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 MENORRHAGIA
• 7.3 SURGICAL BLEEDING CONTROL
• 7.4 TRAUMA AND INJURY
• 7.5 HEREDITARY ANGIOEDEMA (HAE)
• 7.6 POSTPARTUM HEMORRHAGE
• 7.7 OTHERS

8 GLOBAL TRANEXAMIC ACID MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & CLINICS
• 8.3 AMBULATORY SURGICAL CENTERS
• 8.4 OTHERS

9 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITION DASHBOARD
  • 10.3.1 PRODUCT PORTFOLIO
  • 10.3.2 REGIONAL PRESENCE
  • 10.3.3 STRATEGIC ALLIANCES
  • 10.3.4 INDUSTRY EXPERIENCES
• 10.4 WHO ARE THE MAJOR DISRUPTORS & INNOVATORS
• 10.5 WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 Merger and Acquisition
  • 10.6.2 Product launch

11 COMPANY PROFILES

• 11.1 PFIZER INC
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 Key Strategy
• 11.2 FRESENIUS KABI USA, LLC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 Key Strategy
• 11.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 Key Strategy
• 11.4 MAXWELLIA LTD.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 PRODUCTS OFFERED
  • 11.4.3 KEY DEVELOPMENTS
  • 11.4.4 SWOT ANALYSIS
  • 11.4.5 Key Strategy
• 11.5 AUROBINDO PHARMA USA
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 PRODUCTS OFFERED
  • 11.5.3 KEY DEVELOPMENTS
  • 11.5.4 SWOT ANALYSIS
  • 11.5.5 Key Strategy
• 11.6 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 Key Strategy
• 11.7 APOTEX INC.
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 PRODUCTS OFFERED
  • 11.7.3 KEY DEVELOPMENTS
  • 11.7.4 SWOT ANALYSIS
  • 11.7.5 Key Strategy
• 11.8 FERRING PHARMACEUTICALS
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 PRODUCTS OFFERED
  • 11.8.3 KEY DEVELOPMENTS
  • 11.8.4 SWOT ANALYSIS
  • 11.8.5 Key Strategy
• 11.9 NORDIC PHARMA, INC
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 PRODUCTS OFFERED
  • 11.9.3 KEY DEVELOPMENTS
  • 11.9.4 SWOT ANALYSIS
  • 11.9.5 Key Strategy
• 11.10 EXELA PHARMA SCIENCES LLC
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 PRODUCTS OFFERED
  • 11.10.3 KEY DEVELOPMENTS
  • 11.10.4 SWOT ANALYSIS
  • 11.10.5 Key Strategy

12 DATA CITATIONS